Abstract. The protein CD24 is a cell surface protein that appears to function as an adhesion molecule; its expression has been shown to correlate with prognosis in a variety of tumors. Herein, we investigated the possible role and mechanism of CD24 in cervical cancer. Our results showed that CD24 was overexpressed in cervical cancer tissues compared with that in the adjacent non-cancerous tissues by qPCR, immunohistochemistry and western blotting technologies. To explore the possible mechanism of CD24 in cervical cancer, we elucidated the effect of CD24 on the proliferation and apoptosis of cervical cancer HeLa cells and found that a considerable increase in cell proliferation was observed in the HeLa cells with CD24 overexpression. The rate of cell apoptosis was decreased in the HeLa/CD24 cells compared with the HeLa or HeLa/vector cells. Cell apoptosis is closely related with a reduction in mitochondrial membrane potential ($\Delta \Psi_m$) and an increase in intracellular reactive oxygen species (ROS) and calcium ion ($Ca^{2+}$) concentrations. Our results showed that overexpression of CD24 in the cervical cancer HeLa cells, led to an increase in $\Delta \Psi_m$ and a decrease in intracellular ROS and $Ca^{2+}$ concentrations. Furthermore, we found that CD24 was correlated with dysregulation of the MAPK signaling pathway in cervical cancer tissues in vitro. At the same time, we found that CD24 overexpression affected the expression of p38, JNK2 and c-Jun in vitro. In summary, our results suggest that CD24 is upregulated in cervical cancer tissues and plays its functions by affecting the MAPK signaling pathway in cervical cancer.

Introduction

Cervical cancer is the second most prevalent cancer in females worldwide (1). Human papillomavirus (HPV) infection is a sexually transmitted infection and is a risk for cervical cancer. However, in addition to HPV infection, other factors exist that influence the risk of developing cervical cancer (2,3). Dysregulated activation of many genes, such as CD44, CD24, CD38, FRA-1 and SOX9 has been implicated in cervical cancer (4-8). miRNAs are closely related to the occurrence and regulation of cervical cancer (9). However, the etiology of cervical carcinoma remains poorly understood.

Cluster of differentiation (CD) 24 was originally described as a B lymphocyte marker. CD24 is a heavily glycosylated cell surface protein that appears to be associated with aggressive cancers involving invasion and metastasis (10,11). Huang and Lee found that CD24 overexpression is a predictor of decreased long-term survival in patients with cervical carcinoma and that CD24 expression is a potential prognostic biomarker for cervical carcinomas (12). Sung et al found that CD24 expression is an independent prognostic marker in patients with cervical squamous cell carcinoma, even following...
adjuvant treatment after surgery. The results showed that new therapeutic strategies targeting CD24 expression stratified by subgroups may have important clinical implications (13). Kwon et al suggested that CD24 expression is a significant independent prognostic factor for distant metastasis-free survival in patients with uterine cervical squamous cell carcinoma (14). Although some evidence was reported, the significant roles of CD24 in cervical cancer development are still elusive.

In the present study, we examined the expression levels of CD24 in cervical cancer tissues. At the same time, we studied the influence of CD24 on the cell proliferation and apoptosis in a cervical cancer cell line and explored the possible mechanisms.

Materials and methods

Cell culture. One identified general human cervical cancer cell line, HeLa, was cultured in RPMI-1640 (HyClone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco by Life Technologies™, Grand Island, NY, USA), 100 U/ml penicillin, and 100 µg/ml streptomycin (GE Healthcare Life Sciences, Logan, UT, USA) at 37˚C in the presence of 5% CO₂.

Patient samples. Sixteen participants were recruited at the Cancer Hospital of Hunan Province, Central South University (Changsha, Hunan, China). Consent forms were obtained from individual patients, and experimental protocols were approved by the Institutional Review Board of the Cancer Hospital of Hunan Province. All subjects enrolled in the study were Chinese. All clinical and biological data were available for the samples (Table I). Cervical cancer tissue and corresponding non-tumor normal tissue were collected, and each biopsy sample was divided into two sections; one was submitted for routine histological diagnosis, and the remaining section was used for qPCR, immunohistochemistry (IHC) and western blotting experiments.

Total RNA extraction and quantitative real-time PCR (qRT-PCR) analysis. Total RNA was extracted from the cervical cancer and corresponding non-tumor normal tissues using TRIzol reagent and cDNA synthesis was carried out using the RevertAid First Strand cDNA Synthesis kit (both from CWBio, Beijing, China) according to the manufacturer's recommendations. qRT-PCR was carried out with GoTaq qPCR Master Mix (Promega, Fitchburg, WI, USA). For detection of CD24 mRNA expression levels, GAPDH was amplified in parallel as an internal control. The sequences of the primers used for qPCR were as follows: CD24 forward, 5'acctgcgagtctcaatgtgacgt-3', reverse, 5'ggcggcgaattcttaagagtagagatgcagaa-3'; GAPDH forward, 5'gcagagagactgcgaagcctg-3' and reverse, 5'actgagtgtggatttattcca-3'; GAPDH primers are specific to each of the target genes was calculated using the 2-ΔΔCt method (15-19). qPCR was carried out with the Bio-Rad CFK96™ Real-Time System (Bio-Rad, Hercules, CA, USA). The data were analyzed by Bio-Rad CFK Manager software (Bio-Rad). Expression of mRNA was assessed by evaluated CT values and GAPDH was used as an internal control.

IHC and evaluation of staining. IHC was carried out using the peroxidase anti-peroxidase technique following a microwave antigen retrieval procedure. The antibody for CD24 was purchased from Boster Biotechnology (Wuhan, China). The antibody against CD24 (1:100) was overlaid on cervical cancer and corresponding non-tumor normal tissue sections and incubated overnight at 4˚C. Secondary antibody incubation (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was performed at room temperature for 30 min. Color reaction was developed using a 3,3-diaminobenzidine tetrachloride (DAB) chromogen solution. All slides were counterstained with hematoxylin. Positive control slides were included in every experiment in addition to the internal positive controls. The specificity of the antibody was determined with matched IgG isotype antibody as a negative control.

Sections were blindly evaluated by two investigators in an effort to provide a consensus on staining patterns by light microscopy (Olympus). CD24 staining was assessed according to the methods described by Hara and Okayasu (20) with minor modifications. Each case was rated according to a score that added a scale of intensity of staining to the area of staining. At least 10 high-power fields were randomly chosen, and >1,000 cells were counted for each section. The intensity of staining was graded on the following scale: 0, no staining; 1+, mild staining; 2+, moderate staining; and 3+, intense staining. The area of staining was evaluated as follows: 0, no staining of cells in any microscopic fields; 1+, <30% of the tissue stained positive; 2+, between 30 and 60% of the tissue stained positive; 3+, >60% of the tissue stained positive. The minimum score when summed (extension + intensity) was, therefore, 0; and the maximum, 6. A combined staining score (extension + intensity) of ≤2 was considered to be negative staining (low staining); a score between 3 and 4 was considered to be moderate staining; whereas a score between 5 and 6 was considered to be strong staining. An optimal cut-off level was identified as follows: a staining index score of 0-2 was used to define tumors with negative expression and 3-7 indicated positive expression of these two proteins. Agreement between the two evaluators was 95%, and all scoring discrepancies were resolved through discussion between the two evaluators.

Construction of the pEGFP-N1-CD24 vector and cell transfection. The coding region of the CD24 gene was generated by PCR with the primer pair: 5'-tattattacagaggtggagactgtggc-3' and 5'-ggcgccgattaaagctgttagatgctga-3'. PCR was performed under the following conditions: one cycle for 5 min at 94˚C, 30 cycles for 45 sec at 94˚C, 45 sec at 55˚C, and 90 sec at 72˚C, and ended with 10 min at 72˚C. The fragments were cloned into the TA vector (Promega) and used to transform E. coli JM109 (Takara, Dalian, China). Following selection and propagation, the pure plasmid DNA was prepared by standard methods. The DNA fragments were removed from the TA vector by restriction enzyme digestion with XhoI and EcoR1 (Promega) to subclone into the pEGFP-N1 vector. The fusion sequences were verified by DNA sequencing using ABI 3730. To establish a stable CD24-expressing cell line, the plasmid pEGFP-N1/CD24 or control empty vector pEGFP-N1 was tranfected into the HeLa cells, using Lipofectamine (Invitrogen Life Technologies, Carlsbad, CA, USA) according
to the manufacturers’ instructions, followed by G418 selection. The stable transfectants, HeLa/CD24 and HeLa/vector, were isolated and the transcription of CD24 protein was determined by qPCR and western blot experiments.

In vitro CCK-8 assay for cellular viability. Cell viability was measured with Cell Counting Kit-8 (CCK-8) assay (7Sea Pharmatech Co., Ltd., Shanghai, China). Cells were prepared in 96-well cell culture plates at a cellular density of 5x10^3 cells/well for the HeLa/CD24, HeLa/vector and HeLa cells at 37˚C for 24 h. The cell monolayer was washed three times with phosphate-buffered saline (PBS) containing 1.2 mM CaCl2 and 0.7 mM MgCl2. Then a 1:10 diluted CCK-8 solution in RPMI-1640 was added to the cells and incubated for 2 h at 37˚C. The results were measured by a microplate reader at 450 nm and are expressed as percentages of the control values. All experiments were conducted in triplicate.

Colony formation assay. Approximately 500 HeLa/CD24, HeLa/vector and HeLa cells were plated in a 6-well plate with triplicate repeats for each cell group to detect the colony formation efficiency (CFE). When the clone contained >50 cells, we washed the plate with PBS and fixed the cells in 4% paraformaldehyde at room temperature for 10 min. The cells were washed twice and stained with crystal violet for 20 min and then the clone number was counted. The CFE was calculated as: Ratio = (the clone number/the number of planted cell) x 100%.

Invasion assay. A total of 2x10^4 HeLa/CD24, HeLa/vector and HeLa cells were re-suspended in serum-free RPMI-1640 medium and were seeded into a Matrigel (BD Biosciences, Franklin Lakes, NJ, USA.)-coated polycarbonate membrane in the upper chambers of a Transwell apparatus (Corning, NY, USA). The lower chambers were loaded with 15% FBS RPMI-1640 medium. Forty-eight hours later, some of the cells invaded to the lower surface of the upper chambers. Cells on the top surface of the upper chambers were removed by a cotton swab. Cells that invaded to the lower surface were fixed in 10% formaldehyde, and stained with crystal violet. The cells were observed under a microscope and counted in five different fields (magnification, x100). The assay was repeated in at least three independent experiments.

Effect of CD24 on cervical cancer cell apoptosis. Cell apoptosis was analyzed by flow cytometric analysis using a MoFlo™ XDP High-Performance Cell Sorter (Beckman Coulter, Brea, CA, USA), propidium iodide (PI) and Hoechst 33342 double staining (Nanjing KeyGen Biotech Co., Ltd., Nanjing, China). Briefly, the HeLa cells (HeLa, HeLa/vector and HeLa/CD24) were seeded at a density of 1x10^5 cells/well into 6-well culture plates. The cells were collected in an Eppendorf tube at 24 h and washed twice with PBS by centrifugation. The supernatants were discarded. To detect apoptosis, 500 µl PBS, 5 µl Hoechst 33342 and 5 µl PI were added to each tube, and the contents of the tube were mixed in the dark at room temperature for 15 min, followed by FCM testing (Beckman Coulter). Data were acquired and analyzed using Summit v5.2 software (Beckman Coulter).

Detection of mitochondrial membrane potential by JC-1. The impact of CD24 was measured by flow cytometry using the sensitive and relatively mitochondrion-specific lipophilic cationic probe fluorochrome JC-1. JC-1 accumulates to form J-aggregates and emits red fluorescence in the mitochondria with high membrane potential, yet dissociates into monomers and emits green fluorescence in those that lose cross-membrane electrochemical gradient. The cells were suspended in a 6-well plate at 37˚C for 24 h and washed twice with PBS by centrifugation. The supernatants were discarded. To detect mitochondria, 500 µl PBS, 5 µl JC-1 and 2 µl PI were added to each tube, and the contents of the tube were mixed in the dark at room temperature for 15 min, followed by FCM testing (Beckman Coulter). Data were acquired and analyzed using Summit v5.2 software (Beckman Coulter).

### Table I. Characteristics of the cervical cancer patients.

<table>
<thead>
<tr>
<th>Sample</th>
<th>Age, years</th>
<th>HPV type</th>
<th>Histological diagnosis</th>
<th>Stagea</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>46</td>
<td>16</td>
<td>Cervical intermediately differentiated squamous cell cancer</td>
<td>IIa2</td>
</tr>
<tr>
<td>2</td>
<td>60</td>
<td>16</td>
<td>Cervical intermediately differentiated squamous cell cancer</td>
<td>IIa2</td>
</tr>
<tr>
<td>3</td>
<td>60</td>
<td>16, 53, 58</td>
<td>Cervical poorly differentiated squamous cell cancer</td>
<td>IIb</td>
</tr>
<tr>
<td>4</td>
<td>47</td>
<td>16</td>
<td>Cervical intermediately differentiated squamous cell cancer</td>
<td>IIb</td>
</tr>
<tr>
<td>5</td>
<td>49</td>
<td>18</td>
<td>Cervical highly differentiated squamous cell cancer</td>
<td>IIb</td>
</tr>
<tr>
<td>6</td>
<td>49</td>
<td>6</td>
<td>Cervical poorly differentiated squamous cell cancer</td>
<td>IIa</td>
</tr>
<tr>
<td>7</td>
<td>43</td>
<td>16</td>
<td>Cervical intermediately differentiated squamous cell cancer</td>
<td>IIb</td>
</tr>
<tr>
<td>8</td>
<td>48</td>
<td>16</td>
<td>Cervical intermediately differentiated squamous cell cancer</td>
<td>IIb</td>
</tr>
<tr>
<td>9</td>
<td>40</td>
<td>16, CP8304</td>
<td>Cervical intermediately differentiated squamous cell cancer</td>
<td>IIb</td>
</tr>
<tr>
<td>10</td>
<td>46</td>
<td>16</td>
<td>Cervical intermediately differentiated squamous cell cancer</td>
<td>IIb</td>
</tr>
<tr>
<td>11</td>
<td>39</td>
<td>16</td>
<td>Cervical intermediately differentiated squamous cell cancer</td>
<td>IIb</td>
</tr>
<tr>
<td>12</td>
<td>56</td>
<td>(-)</td>
<td>Cervical poorly differentiated squamous cell cancer</td>
<td>IIa</td>
</tr>
<tr>
<td>13</td>
<td>50</td>
<td>16</td>
<td>Cervical poorly differentiated squamous cell cancer</td>
<td>IIa</td>
</tr>
<tr>
<td>14</td>
<td>46</td>
<td>16</td>
<td>Cervical intermediately differentiated squamous cell cancer</td>
<td>IIb</td>
</tr>
<tr>
<td>15</td>
<td>36</td>
<td>16, 58</td>
<td>Cervical poorly differentiated squamous cell cancer</td>
<td>IIa</td>
</tr>
<tr>
<td>16</td>
<td>60</td>
<td>59</td>
<td>Cervical intermediately differentiated squamous cell cancer</td>
<td>IIb</td>
</tr>
</tbody>
</table>

aThe International Federation of Gynecologists and Obstetricians (FIGO) stage: 2009. HPV, human papillomavirus.
in 1 ml of warm staining buffer at ~1x10⁶ cells/ml and were incubated at 37˚C for 5 min. Then 1 µl of 2 mM JC-1 (2 µM final concentration) was added and the cells were incubated at 37˚C in 5% CO₂ for 15-30 min. The cells were pelleted by centrifugation, resuspended by gently flicking the tubes, and 500 µl PBS was added to each tube. Cells were analyzed with a MoFlo™ XDP High-Performance cell sorter. Data were acquired and analyzed using Summit v5.2 software.

**Intracellular ROS measurement.** The production of intracellular reactive oxygen species (ROS) was measured by performing flow cytometry using the oxidation-sensitive probe, 2',7'-dichlorofluorescein diacetate (DCFH-DA) (Applyingen, Beijing, China). Briefly, 10 mM DCFH-DA stock solution (in methanol) was diluted 4,000-fold in cell culture medium without serum or other additives to yield a 2.5 mM working solution. After the exposure of human umbilical endothelial cells (HUVECs) to silica nanoparticles for 3 and 24 h, respectively, the cells in 6-well plates were washed twice with PBS and incubated in 2 ml working solution of DCFH-DA at 37˚C for 30 min. Then the cells were washed twice with cold PBS and resuspended in the PBS for analysis of intracellular ROS by FACS (Beckman Coulter).

**Intracellular Ca²⁺ concentration assay.** Intracellular Ca²⁺ concentration was measured by means of the fluorescent Ca²⁺ chelator Fura-2 AM, which permeates into cells where it is cut into Fura-2, resorting within the cells. Fura-2 combines with intracellular Ca²⁺ to form a fluorescent compound, whose fluorescent intensity is determined at excitation wavelength 340 nm and emission wavelength 510 nm in FACS. After treatment, the cells were harvested and rinsed with PBS. The harvested cells were suspended in PBS and incubated with 5 µM Fura-2 AM for 60 min at 37˚C. During the session of incubation with Fura-2 AM, cell cultures were mildly shaken at intervals of 10 min aimed to facilitate the combination of Fura-2 and Ca²⁺ to form the fluorescent compound. Then, the cells were washed twice and resuspended in PBS for FACS measurement. Data were acquired and analyzed using Summit v5.2 software.

**Western blot analysis.** The cervical cancer tissues, corresponding non-tumor normal tissues, and HeLa cells were lysed in RIPA buffer (CWBio), and the total protein concentration was determined using Pierce® BCA protein assay kit (Thermo Scientific, Inc., Rockford, IL, USA). Extracts containing 50 µg of proteins were separated on 10% SDS-PAGE gels and electroblotted onto nitrocellulose membranes (HyClone Laboratories). The membranes were incubated using tris-buffered saline/Tween-20 (25 mM Tris-HCl, 150 mM NaCl, pH 7.5 and 0.05% Tween-20) containing 5% non-fat milk followed by overnight incubation at 4°C with the primary antibodies [rabbit anti-human p38 antibody (1:200; catalog no. B7178; Anbo Biotechnology Company, Changzhou, China); rabbit anti-human JNK2 antibody (catalog no. sc-827) and rabbit anti-human c-Jun antibody (1:500; catalog no. sc-1694; Santa Cruz Biotechnology, Inc.); and rabbit anti-Fra-1 antibody (1:300; ImmunoWay Biotechnology Co.,)].

Following three washes, the membranes were incubated with a horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Inc.), and the specific signals were visualized using an ECL detection system. Anti-GAPDH antibody (1:3,000; Santa Cruz Biotechnology, Inc.) was used as a loading control.

**Statistical analysis.** Differences in non-parametric variables were analyzed by the Mann-Whitney U test. Differences in the quantitative variables between groups were analyzed by Student’s t-test using SPSS 11.0 program (SPSS, Inc., Chicago, IL, USA). A value of p<0.05 was considered to indicate a statistically significant result.

**Results**

**CD24 is highly expressed in cervical cancer tissues.** To detect the mRNA expression levels of the CD24 molecule in the cervical cancer and adjacent non-cancerous tissues, 16 samples of each were selected to perform qPCR of the CD24 gene. The data were analyzed using the 2⁻ΔΔCt method and the fold-change in the expression of these genes relative to the internal control gene, GAPDH, was analyzed. The expression of the CD24 gene was higher in the cervical cancer samples compared with the adjacent non-cancerous tissues, and the normalized CD24 gene expression in cervical cancer was upregulated by 3.29-fold (Table II).

To determine whether the CD24 gene is expressed at a higher level in cervical cancer compared with the adjacent non-cancerous tissues, the protein expression levels of CD24 were further examined by western blotting in 1-4 samples (p<0.01; Fig. 1A). In comparison with the adjacent non-cancerous tissues, the expression level was identified to be greater in the cervical cancer tissues, which corresponded with the qPCR results.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Sample</th>
<th>n</th>
<th>CD24 (mean ± SD)</th>
<th>GAPDH CT (mean ± SD)</th>
<th>ΔCT (mean ± SD)</th>
<th>ΔΔCT (mean ± SD)</th>
<th>Fold^a</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD24</td>
<td>Cervical</td>
<td>16</td>
<td>28.31±1.05</td>
<td>18.67±0.64</td>
<td>9.64±0.43</td>
<td>-1.72±0.38</td>
<td>3.29</td>
</tr>
<tr>
<td></td>
<td>Non-cancerous</td>
<td>16</td>
<td>29.24±1.12</td>
<td>17.88±0.58</td>
<td>11.36±0.45</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

^aMean fold-change in expression of the target gene, CD24, relative to the internal control gene, GAPDH, was calculated using the 2⁻ΔΔCt equation previously adopted by Livak and Schmittgen (15): ΔΔCT = (CTtarget - CTGAPDH) cervical cancer - (CTtarget - CTGAPDH) control. At least three replicates of each reaction were performed. CT, threshold cycle; qPCR, quantitative polymerase chain reaction.
To confirm the pattern of CD24 in cervical cancer, IHC was carried out with antibodies against CD24 protein in the cervical cancer and the adjacent non-cancerous tissues. CD24 was identified as being differentially expressed between the cervical cancer tissues and the adjacent non-cancerous tissues. IHC showed a similar pattern in protein expression with the western blot results. A high score for CD24 was noted in 56.25% (9/16) of the cervical cancer tissues and 18.75% (3/16) of the adjacent non-cancerous tissues. A low score was found in 12.50% (2/16) and 68.75% (11/16) of the cervical cancer and the adjacent non-cancerous tissues, respectively (p=0.0097<0.01) (Fig. 1B and Table III). This corresponded with the qPCR results.

To elucidate the function of CD24 in the growth

**Table III.** The difference in CD24 expression between the cervical cancer and the adjacent non-cancerous tissues.

<table>
<thead>
<tr>
<th>Score</th>
<th>Low (0-2)</th>
<th>Moderate (3-4)</th>
<th>High (5-6)</th>
<th>( \chi^2 )</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical cancer</td>
<td>16</td>
<td>2 (12.50)</td>
<td>5 (31.25)</td>
<td>9 (56.25)</td>
<td>9.26</td>
</tr>
<tr>
<td>Non cancerous tissues</td>
<td>16</td>
<td>11 (68.75)</td>
<td>4 (25.00)</td>
<td>3 (18.75)</td>
<td></td>
</tr>
</tbody>
</table>

p<0.01 by Mann-Whitney U test.

**CD24 promotes the growth and invasion of cervical cancer cells in vitro.** To elucidate the function of CD24 in the growth
of cervical cancer cells, the HeLa cells were transfected with the plasmid pEGFP-N1/CD24 or the control vector to generate CD24-stable expressing HeLa/CD24 or control HeLa/vector cell lines. After demonstrating CD24 mRNA transcription by RT-PCR (Fig. 2A), the spontaneous proliferation of HeLa, HeLa/vector and HeLa/CD24 cells was determined by the CCK-8 assay (Fig. 2B). Clearly, CD24 significantly promoted the proliferation of HeLa cells. Therefore, endogenous CD24 overexpression promoted the proliferation of HeLa cells in vitro.

At the same time, HeLa, HeLa/vector and HeLa/CD24 cells were cultured into a 6-well plate and CFE was observed during 12 days of culture. After the 12 days, HeLa/CD24 cells grew well and most clones had reached >50 cells, but HeLa and HeLa/vector cells had fewer cells attached to the plates and formed smaller clones compared to the HeLa/CD24 cells.
We counted the number of clones and the statistical analysis showed significant differences in CFE among the HeLa, HeLa/vector and HeLa/CD24 cells (p<0.01; Fig. 2C and D).

Cell invasion is an important step during tumor metastasis. Thus, we detected the invasion ability of the HeLa, HeLa/vector and HeLa/CD24 cells by Transwell assay in vitro. We found that more HeLa/CD24 cells migrated through the Matrigel than HeLa and HeLa/vector cells by Transwell assay in vitro. The results showed that the HeLa/CD24 cells had higher invasive ability compared to the HeLa and HeLa/vector cells.

**CD24 inhibits the apoptosis of cervical cancer cells in vitro.** We found that CD24 was highly expressed in the cervical cancer tissues by qPCR, western blotting and IHC technologies. To elucidate the function of CD24 in the apoptosis of cervical cancer cells, the apoptosis of HeLa, HeLa/vector and HeLa/CD24 cells was tested. We performed a Hoechst 33342/PI double-staining experiment to test the rate of apoptosis in the HeLa, HeLa/vector and HeLa/CD24 cells. A considerable decrease in the percentage of apoptotic cells was observed for HeLa/CD24 (3.67±0.28%), HeLa/vector (9.41±0.83%) and HeLa cells (10.25±0.92%) (Fig. 3A).

**CD24 affects the mitochondrial membrane potential (ΔΨm), ROS and calcium ion (Ca2+) concentrations of cervical cancer cells in vitro.** Cell apoptosis is closely related with a reduction in ΔΨm and an increase in intracellular ROS and Ca2+ concentrations. Thus, we tested the influence of CD24 on these three parameters. Our results showed that overexpression of CD24 in cervical cancer HeLa cells, led to an increase in ΔΨm and inhibition of cell apoptosis (Fig. 3B). ROS results showed that overexpression of CD24 in the HeLa cells, led to a decrease in intracellular ROS (Fig. 3C). Ca2+ experiment results showed that overexpression of CD24 in the HeLa cells, led to a decrease in Ca2+ concentrations and suppressed the apoptosis of cervical cancer cells (Fig. 3D).

**CD24 is correlated with dysregulation of the MAPK signaling pathway in cervical cancer tissues.** To uncover the possible mechanism of CD24 in cervical cancer, we tested the expression levels of key molecules in the MAPK signaling pathway by western blotting. p38, JNK2 and c-Jun were upregulated in the cervical cancer compared with levels in the adjacent non-cancerous tissues (Fig. 4A). Since CD24 was highly expressed in the cervical cancer tissues, we inferred that CD24 was correlated with dysregulation of the MAPK signaling pathway in cervical cancer tissues in vitro. A positive correlation may exist between the expression of CD24 and the MAPK signaling pathway in cervical cancer.

**CD24 overexpression affects the expression of p38, JNK2 and c-Jun in vitro.** To confirm whether CD24 affects the expression of p38, JNK2 and c-Jun in vitro, we detected the expression levels of p38, JNK2 and c-Jun in the HeLa, HeLa/vector and HeLa/CD24 cells by western blotting. The results showed that p38, JNK2 and c-Jun proteins were highly expressed in the HeLa/CD24 cells compared with levels in the HeLa and HeLa/vector cells (Fig. 4B). These results suggest that CD24 overexpression affects the expression of p38, JNK2 and c-Jun in vitro.

**Discussion**

Cervical cancer is the second most common gynecological malignancy threatening the health of women worldwide and remains a leading cause of cancer-related deaths in women in developing countries (1-3, 21-23). One major cause is persistent infection of HPV, leading to abnormal epithelial lesions, with progression to precancerous and invasive cancer (24,25). Dysregulated activation of other genes, such as CD24 and CD44, influences the risk of developing cervical cancer (4-8). Thus, sensitive and specific biomarkers for the early detection of cervical cancer are urgently required to reduce the high morbidity and mortality of this disease.

In the present study, we found that the expression of the CD24 gene was higher in the cervical cancer samples when compared with that in the adjacent non-cancerous tissues and the normalized CD24 gene expression in cervical cancer was upregulated by 3.29-fold. There was a similar tendency noted by western blot experiments. IHC showed a similar pattern in protein expression with qPCR and western blot results. A high score of CD24 was noted in 56.25% (9/16) of the cervical cancer tissues and 18.75% (3/16) of the adjacent non-cancerous tissues. Huang and Lee found that CD24 was overexpressed in invasive cervical carcinoma (12). Kwon et al results showed that positive staining of CD24 expression was found in 58.9% of the cases (14). Our results corresponded with their results.
To uncover the potential mechanism of CD24 in cervical cancer, we studied the effect of CD24 on the proliferation, invasion and apoptosis of cervical cancer HeLa cells. Our results showed that there was a considerable increase in proliferation and invasion of HeLa cells with CD24 overexpression. Compared with the HeLa cells, the rate of apoptotic cells was decreased in the HeLa cells with CD24 overexpression. Overexpression of CD24 in laryngeal squamous cell carcinoma is associated with invasiveness, metastatic potential and high tumor proliferation status (26). Wang et al found that CD24 was associated with enhanced invasiveness of gastric carcinogenesis and a poor prognosis (27). Leelawat et al showed that CD24 expression is linked to the aggressiveness of cholangiocarcinoma cells and the adverse prognosis of cholangiocarcinoma patients (28). CD24 enhanced DNA damage-induced apoptosis by modulating NF-κB signaling in CD44-expressing breast cancer cells (29). Moreover, CD24 affects the occurrence and development of malignant tumors by cell proliferation, cell invasion and cell apoptosis.

Furthermore, to explore the possible mechanism of CD24 in cervical cancer, we tested the expression levels of key molecules (p38, JNK2 and c-Jun) in the MAPK signaling pathway. Compared with the adjacent non-cancerous tissues, p38, JNK2 and c-Jun were upregulated in the cervical cancer tissues. Thus, a positive correlation between the expression of CD24 and key molecules of the MAPK signaling pathway exist in cervical cancer tissues. At the same time, we studied the effect of the overexpression of CD24 on p38, JNK2 and c-Jun in vitro. The results showed that overexpression of CD24 may upregulate the expression of p38, JNK2 and c-Jun in HeLa cells. MAPKs transduce extracellular signals into a variety of cellular processes, such as cell proliferation, survival, death and differentiation (30). JNK is a family of protein kinases, which are activated by stress stimuli and regulate various cellular processes including proliferation, apoptosis and survival (31).

In summary, our results suggest that CD24 promoted the proliferation and inhibited the apoptosis of cervical cancer cells through the MAPK signaling pathway.

Acknowledgements

The present study was supported by the National Natural Science Foundation of China (81272975, 81172302, 81402270 and 81402307), the Key Project of Hunan Provincial Natural Science Foundation (12JJ2044), the Project of Hunan Provincial Natural Science Foundation (12JJ3121), the Project of Hunan Provincial Development and Reform Commission, the Planned Science and Technology Project of Hunan Province (2010FJ3088, 2012FJ2014 and 2015JC3024), the Planned Project of Department of Health of Hunan Province (B2015-042), and the Hunan Provincial Innovation Foundation for Postgraduates.

References


In summary, our results suggest that CD24 promoted the proliferation and inhibited the apoptosis of cervical cancer cells through the MAPK signaling pathway.

Acknowledgements

The present study was supported by the National Natural Science Foundation of China (81272975, 81172302, 81402270 and 81402307), the Key Project of Hunan Provincial Natural Science Foundation (12JJ2044), the Project of Hunan Provincial Natural Science Foundation (12JJ3121), the Project of Hunan Provincial Development and Reform Commission, the Planned Science and Technology Project of Hunan Province (2010FJ3088, 2012FJ2014 and 2015JC3024), the Planned Project of Department of Health of Hunan Province (B2015-042), and the Hunan Provincial Innovation Foundation for Postgraduates.